CVS Health Q2 Sales Up Across Insurance & Pharmacy, Lifts Annual Outlook

  • CVS Health Corp's CVS Q2 sales increased 11% Y/Y to $80.6 billion, beating the consensus of $76.37 billion.
  • Prescriptions filled increased 1.6% on a 30-day equivalent basis, driven by increased utilization and the impact of an extended cough, cold, and flu season, partially offset by decreased COVID-19 vaccinations. 
  • Excluding the impact of COVID-19 vaccinations, prescriptions filled increased 4.6% on a 30-day equivalent basis.
  • Total pharmacy claims processed increased 3.9% on a 30-day equivalent basis and up 5.7%, excluding COVID-19 vaccinations.
  • Retail sales were bolstered by increased prescription and front-store volume, which included at-home Covid-19 testing kits. Retail sales reached $26.29 billion (+6.3%).
  • Adjusted EPS was $2.40, beating the consensus of $2.17.
  • Outlook: CVS Health raised the adjusted EPS outlook to $8.40 - $8.60, up from previous guidance of $8.20 - $8.40, compared to the consensus of $8.36. 
  • The company also raised FY22 cash flow from operations guidance to $12.5 - $13.5 billion compared to $12 - $13.0 billion expected earlier.
  • Price Action: CVS shares are up 4.01% at $99.19 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!